The effects of intravenous disopyramide phosphate on myocardial function were evaluated by non-invasive indices of cardiac performance (systolic time intervals, STI) in 15 patients with atherosclerotic heart disease and different degrees of cardiac failure. Disopyramide (1.5mg/ Kg) was given intravenously over a period of 5min. This drug induced in patients in I-II classes of NYHA a significant decrease of LVETc, while PEP, ICT, and PEP/LVET ratio rose significantly.
drug were more marked in this group than in the group of patients in classes I-II, at least for the indices of contractility. Actually, by comparing changes induced on STI by the drug in the 2 groups of patients, it was shown that the increase in PEP, ICT, and PEP/LVET ratio following disopyramide was significantly greater in patients in III-IV classes, as compared to those in I-II classes (Fig. 2) . In contrast, LVETc, which correlates to stroke volume, was similarly worsened by the drug in the 2 groups of patients (Fig. 2) . These changes of STI became evident after 5-10min and disappeared about 30 min after the administration of the drug. In contrast, heart rate and systemic arterial blood pressure were not significantly modified (Table I) . No side effects were observed throughout the study.
DISCUSSION
The efficacy of disopyramide in interrupting different types of arrhythmias has been demonstrated.1)-3) In particular, this drug proved to be specially active on ventricular arrhythmias, such as ventricular tachycardia and threatening premature ventricular contractions. 14)-26) Moreover, the hemodynamic effects of this antiarrhythmic and its depressant action on cardiac contractility were explored in the experimental animal8),9) as well as in healthy men.10) However, little information is available concerning its effects on cardiac performance in patients with heart disease and the possible different actions of disopyramide in subjects with different degrees of cardiac failure. To evaluate cardiac performance, the non-invasive measurement of STI was preferred to invasive indices. The reason for this choice was that in obtaining the indices of cardiac performance invasively, results could be altered by the emotional stress, and the consequent catecholamines release always connected with invasive studies. Furthermore, invasive indices cannot be corrected for heart rate and, thus, changes in this parameter can lead to a misinterpretation of the data. The results of this study confirm the depressant effects of the drug on cardiac performance, as shown by changes in most of the J ap. Heart J. 
